gr en
Text size
  • Home
  • About us
  • Services
  • Relevant Articles
    • Dementia
    • Mental Empowerment
    • Fall risks
    • Chronic diseases
    • Care of people
    • Social Policy
    • Alzheimer
  • Projects
    • European Projects
      • Techcare
      • Radio
      • M3W - AAL II
      • VALUE-AGEING - Marie Curie
      • EQUIP II - LDV - Transfer of Innovation
      • TACT-EUROPE - LLP - Partnerships
      • I-DONT-FALL - ICT - PSP
      • GAMEABLING - FP7 - Research for SME's
      • h-SEAT - LEAD ERA
      • TRUTH - LDV - Transfer of Innovation
      • ERGOCAREBANK - LDV - Transfer of Innovation
    • National Projects
      • Cooperation 2011
  • News
  • F.A.Qs
  • Contact us
Relevant Articles
  • Dementia
  • Mental Empowerment
  • Fall risks
  • Chronic diseases
  • Care of people
  • Social Policy
  • Alzheimer

Share Tools

  • Print Page
  • Share this on Facebook
  • Share this on Twitter

What is Alzheimer's Disease?

Alzheimer's disease (AD) is an age-related, non-reversible brain disorder that develops over a period of years. In the early stages of AD, patients may experience memory impairment, lapses of judgment, and subtle changes in personality. As the disorder progresses, memory and language problems worsen and patients begin to have difficulty performing activities of daily living, such as balancing a checkbook or remembering to take medications.


They also may have visuospatial problems, such as difficulty navigating an unfamiliar route. They may become disoriented about places and times, may suffer delusions (such as the idea that someone is stealing from them or that their spouse is being unfaithful), and may become short-tempered and hostile.


During the late stages of the disease, patients begin to lose the ability to control motor functions. They may have difficulty swallowing and lose bowel and bladder control. They eventually lose the ability to recognize family members and to speak. As AD progresses, it begins to affect the person's emotions and behavior. Most people with AD eventually develop symptoms such as aggression, agitation, depression, sleeplessness, or delusions.


There are three major hallmarks in the brain that are associated with the disease processes of AD:

Amyloid plaques, which are made up of fragments of a protein called beta-amyloid peptide mixed with a collection of additional proteins, remnants of neurons, and bits and pieces of other nerve cells.

Neurofibrillary tangles (NFTs), found inside neurons, are abnormal collections of a protein called tau. Normal tau is required for healthy neurons. However, in AD, tau clumps together. As a result, neurons fail to function normally and eventually die.

Loss of connections between neurons responsible for memory and learning. Neurons can't survive when they lose their connections to other neurons. As neurons die throughout the brain, the affected regions begin to atrophy, or shrink. By the final stage of AD, damage is widespread and brain tissue has shrunk significantly.


Is there any treatment?

Currently there are no medicines that can slow the progression of AD. However, four FDA-approved medications are used to treat AD symptoms. These drugs help individuals carry out the activities of daily living by maintaining thinking, memory, or speaking skills. They can also help with some of the behavioral and personality changes associated with AD. However, they will not stop or reverse AD and appear to help individuals for only a few months to a few years.


Donepezil (Aricept), rivastigmine (Exelon), and galantamine (Reminyl) are prescribed to treat mild to moderate AD symptoms. Donepezil was recently approved to treat severe AD as well. The newest AD medication is memantine (Namenda), which is prescribed to treat moderate to severe AD symptoms.


Frontida Zois provides care givers with the latest in Alzheimer's education and dementia care techniques, so you can be assured your loved one is with a trusted professional. Care givers are trained to:

  • Maintain a safe environment
  • Avoid surrounding objects that could cause disturbance
  • Manage changing behaviors
  • Provide mind-stimulating activities
  • Supervise daily activities

Connect with us: fb twitter linkedin youtube
Frontida Zois | O.N.R Patron Pyrgou 115, P.O. 25002, Patras, Greece | tel. +30 2610 222612, fax. +30 2610 240243